|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 90.86 CHF | -8.92% |
|
-.--% | - |
| 08-10 | Nurix Therapeutics' STAT6 Degrader Likely to Receive Increased Recognition, RBC Says | MT |
| 08-10 | Innate Pharma surges after a deal that secures its cash runway for another year |  |
Evolution of the Average Target: Sanofi
Evolution of the Target Price: Sanofi
Changes in Analyst Recommendations: Sanofi
| Consensus | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Objective/dr gap | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | ||
| +4.92% | |||||
| +4.08% | |||||
| +10.64% | |||||
| -0.75% | |||||
| -1.64% | |||||
| +30.55% | |||||
| -8.54% | |||||
| +2.68% | |||||
| +18.3% | |||||
| Average | +6.69% | |||||
| Weighted average by Cap. | +5.76% |
Analysts' Consensus
Analyst Consensus Detail
Consensus revision (last 18 months)
Analysts covering the company
| JEFFERIES | Michael Leuchten |
| BERNSTEIN RESEARCH | Justin Smith |
| BERENBERG | Luisa Hector |
| DZ BANK | Elmar Kraus |
| UBS | Matthew Weston |
| JPMORGAN | Richard Vosser |
| AlphaValue/Baader Europe | |
| alphavalue | Abhishek Raval |
| GOLDMAN SACHS | James Quigley |
| CIC Corporate & Institutional Banking | |
| Morgan Stanley | |
| BARCLAYS | James Gordon |
| BNP Paribas | |
| DEUTSCHE BANK RESEARCH | Emmanuel Papadakis |
| Bank of America Securities/Merrill Lynch | |
| Guggenheim | |
| Intron Health | |
| Berenberg Bank | |
| CIC Market Solutions | |
| STIFEL | Eric Le Berrigaud |
| CREDIT SUISSE | Dominic Lunn |
| Argus | |
| Kepler Cheuvreux | |
| DEUTSCHE BANK | Emmanuel Papadakis |
| Stifel Nicolaus | |
| Liberum Capital | |
| SVB Leerink | |
| BAADER BANK | |
| Deutsche Bank Securities | |
| ODDO BHF | |
| HSBC | Julie Mead |
| BANK OF AMERICA (BOFA) | Sachin Jain |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- SAN Stock
- SAN Stock
- Consensus Sanofi
Select your edition
All financial news and data tailored to specific country editions
